chronic myelomonocytic leukemia

Mayo Clinic discovery in bone marrow cancer points to potential drug targets

New research finds that patients with ASXL1-mutant chronic myelomonocytic leukemia have distinctive epigenetic changes that can activate harmful genes and cause the cancer to grow faster.